I must make progress. A long queue of Members are waiting to speak. The EMA also leads on research, especially on rare and paediatric diseases. It simply is not possible for a single country to carry out such research. My amendment 351 is intended to ensure that we continue to participate in clinical trials under the clinical trials regulation that will come into effect in April, and maintaining standards of data protection is crucial to that. If we rush into a race to the bottom, we will end up as pariahs and we will simply not be able to co-operate with others. I support amendment 300, which was tabled by the right hon. Member for Wantage (Mr Vaizey) and which concerns Euratom, but I want to clear up one point. The issue of access to a secure supply of medical radioisotopes was raised by the Royal College of Radiologists, but was dismissed by the Government because the isotopes are non-fissile. It is true that they are non-fissile, but we had a catastrophic shortage between 2008 and 2010 as a result of which I, as a breast cancer surgeon, could not carry out my bone scans. The new technique of sentinel node biopsy which was being rolled out had to be delayed and stalled, and I would have to choose which of my patients might have access to the one dose of technetium that we had to do a bone scan. That is why the Euratom Supply Agency set up the European Observatory on the Supply of Medical Isotopes, and it managed the situation. We face real challenges in the coming years. The reactors that produce molybdenum, from which we get technetium, are not in the UK. We do not produce any of that stuff, and we do not yet have a replacement technique as those reactors go offline. It is important for the Government to realise that, if we are not part of the observatory, if we are not participators, the Euratom Supply Agency will have no obligation to us. It might help us, but we will be at the back of the queue, and that will affect patients. New clause 44, tabled by my hon. and learned Friend the Member for Edinburgh South West (Joanna Cherry), calls for an assessment of the impact of Brexit on health and social care and on workforces, especially social care workers. The percentage of EU nationals working in social care is even higher than the percentage in the NHS, but they will not qualify for tier 2-type visas. They are often not highly paid, but we rely on them utterly. Staying in the single market and the customs union would solve all our problems, including the problem of the Irish border, but consideration of that is still being ruled out. I call on the Government to step back from creating all these difficulties, and reconsider the possibility of our staying in the single market and the customs union. The EU is not just about trade; it is also about rights and opportunities, and about co-operation.